Search bioRxiv⌕ Search

Biology subjects

Decker, J. S.

Publications and source records attributed to Decker, J. S..

3 recordsLinked to original sources

Precipitation and Extraction Methods for Protein Purification: A Meta-Analysis of Purification Performance and Cost-Effectiveness

For protein drug purification, packed-bed chromatography often remains both the predominant method and a bottleneck for cost and scalability. Accordingly, extensive efforts have been made to develop alternatives, such as precipitation and liquid-liquid extraction. Despite decades of development, such methods have been slow to see adoption in commercial processes. To diagnose the key barriers to implementation and guide future work, we have systematically reviewed studies of protein precipitation and liquid-liquid extraction. We classify the products, methods, and results of 168 publications representing 290 unique purification operations and analyze these operations in terms of both process economics and purification performance. Whereas it is generally assumed that precipitation and extraction methods will have lower costs than chromatography, we find that this is only the case under specific process conditions such as at a large manufacturing scale and low initial sample purity. Furthermore, we find that only a small number of the many precipitation and extraction methods reported to date have shown readiness for implementation in protein drug purification processes. Finally, we identify key factors governing both the economic and purification performance of this class of methods: first, that operating costs are almost entirely predictable by the ratio between the mass of phase-forming materials used and the mass of product protein yielded; second, that use of modern optimization techniques such as Design of Experiments is associated with significantly better purification performance and cost-effectiveness. HighlightsO_LIAlternative separation purification methods are not always cheaper than chromatography C_LIO_LIThe use of a combination of phase separating agents remains largely underexplored/underutilized C_LIO_LILower initial purity and increasing production scale favor phase-separation over chromatography C_LIO_LIThe direct material usage rate is an important predictor of alternative separation cost-effectiveness C_LIO_LICurrent alternative separation method development has largely ignored optimization of direct material usage rate C_LI

bioengineering↗

Integrated Autolysis, DNA Hydrolysis and Precipitation Enables an Improved Bioprocess for Q-Griffithsin, a Broad-Spectrum Antiviral and Clinical-Stage anti-COVID-19 Candidate

Across the biomanufacturing industry, innovations are needed to improve efficiency and flexibility, especially in the face of challenges such as the COVID-19 pandemic. Here we report an improved bioprocess for Q-Griffithsin, a broad-spectrum antiviral currently in clinical trials for COVID-19. Q-Griffithsin is produced at high titer in E. coli and purified to anticipated clinical grade without conventional chromatography or the need for any fixed downstream equipment. The process is thus both low-cost and highly flexible, facilitating low sales prices and agile modifications of production capacity, two key features for pandemic response. The simplicity of this process is enabled by a novel unit operation that integrates cellular autolysis, autohydrolysis of nucleic acids, and contaminant precipitation, giving essentially complete removal of host cell DNA as well as reducing host cell proteins and endotoxin by 3.6 and 2.4 log10 units, respectively. This unit operation can be performed rapidly and in the fermentation vessel, such that Q-GRFT is obtained with 100% yield and >99.9% purity immediately after fermentation and requires only a flow-through membrane chromatography step for further contaminant removal. Using this operation or variations of it may enable improved bioprocesses for a range of other high-value proteins in E. coli. HighlightsO_LIIntegrating autolysis, DNA hydrolysis and precipitation enables process simplification C_LIO_LIAutolysis reduces endotoxin release and burden to purification C_LIO_LIQ-Griffithsin recovered from fermentation vessel at >99.9% purity and 100% yield C_LIO_LIQ-Griffithsin purified to anticipated clinical grade without conventional chromatography C_LIO_LIThe resulting bioprocess is 100% disposables-compatible, scalable, and low-cost C_LI

synthetic biology↗

Improved, scalable, two-stage, autoinduction of recombinant protein expression in E. coli utilizing phosphate depletion.

We report the improved production of recombinant proteins in E. coli, reliant on tightly controlled autoinduction, triggered by phosphate depletion in stationary phase. The method, reliant on engineered strains and plasmids, enables improved protein expression across scales. Expression levels using this approach have reached as high as 55% of total cellular protein. Initial use of the method in instrumented fed batch fermentations enables cell densities of [~]30 grams dry cell weight (gCDW) per liter and protein titers up to 8.1+/-0.7 g/L ([~]270 mg/gCDW). The process has also been adapted to an optimized autoinduction media, enabling routine batch production at culture volumes of 20 L (384 well plates), 100 L (96 well plates), 20 mL and 100 mL. In batch cultures, cells densities routinely reach [~] 5-7 gCDW per liter, offering protein titers above 2 g/L. The methodology has been validated with a set of diverse heterologous proteins and is of general use for the facile optimization of routine protein expression from high throughput screens to fed-batch fermentation. HighlightsO_LIStationary phase protein expression results in high titers. C_LIO_LIAutoinduction by phosphate depletion enables protein titers from 2-8 g/L. C_LIO_LIAutoinduction has been validated from 384 well plates to instrumented bioreactors. C_LI

synthetic biology↗